Profile data is unavailable for this security.
About the company
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)2.69m
- Net income in HKD-293.84m
- Incorporated2014
- Employees208.00
- LocationAscletis Pharma Inc12F, Building D198 Qidi Road, HIPARKHANGZHOU ChinaCHN
- Websitehttps://www.ascletis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Traditional Chinese Med Hldg CoLtd | 17.71bn | -300.96m | 9.77bn | 15.58k | -- | 0.4152 | 10.70 | 0.5515 | -0.0598 | -0.0598 | 3.52 | 4.67 | 0.4326 | 1.59 | 1.71 | 1,057,360.00 | -0.93 | 3.48 | -1.42 | 5.24 | 47.66 | 54.69 | -2.15 | 7.39 | 1.51 | 9.55 | 0.1333 | 21.27 | -8.90 | 2.89 | -95.79 | -49.14 | -15.28 | -48.82 |
| Hbm Holdings Ltd | 904.99m | 571.49m | 9.91bn | 210.00 | 15.38 | 4.09 | 16.57 | 10.95 | 0.741 | 0.741 | 1.15 | 2.79 | 0.3856 | 6.32 | 32.64 | 5,801,203.00 | 24.77 | -42.87 | 30.77 | -53.24 | 92.95 | 96.12 | 64.25 | -292.58 | 6.02 | 28.63 | 0.1857 | -- | -57.43 | 47.71 | -87.81 | -- | -55.31 | -- |
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -100.00bn | -100.00bn | 11.24bn | 105.00 | -- | 13.17 | -- | -- | -- | -- | -- | 1.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Fujian Haixi Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 11.41bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.39 | -- | 15.86 | -- | -- | -- |
| Everest Medicines Ltd | 967.41m | -748.61m | 11.98bn | 722.00 | -- | 2.49 | -- | 12.38 | -2.32 | -2.32 | 2.99 | 13.62 | 0.1684 | 13.97 | 3.04 | 1,454,751.00 | -13.03 | -29.28 | -14.21 | -31.67 | 69.92 | -- | -77.38 | -1,040.86 | 5.43 | -- | 0.1577 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.38bn | -91.63m | 12.80bn | 2.77k | -- | 2.58 | -- | 5.37 | -0.0098 | -0.0098 | 0.2583 | 0.542 | 0.1894 | 1.49 | 3.86 | 893,796.30 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| Consun Pharmaceutical Group Ltd | 3.71bn | 1.15bn | 14.22bn | 3.07k | 12.65 | 2.91 | 11.63 | 3.83 | 1.34 | 1.34 | 4.33 | 5.80 | 0.5642 | 2.35 | 12.33 | 1,173,505.00 | 17.60 | 14.71 | 24.67 | 22.82 | 76.62 | 75.04 | 31.20 | 29.56 | 3.32 | -- | 0.0517 | 40.93 | 14.56 | 11.42 | 16.05 | 62.72 | -9.54 | 25.83 |
| Ascletis Pharma Inc | 2.69m | -293.84m | 15.30bn | 208.00 | -- | 6.55 | -- | 5,695.75 | -0.3004 | -0.3004 | 0.0028 | 2.20 | 0.0011 | 0.2668 | 11.59 | 11,629.77 | -12.10 | -8.46 | -12.73 | -8.80 | 36.21 | 7.91 | -10,937.78 | -522.12 | 14.53 | -- | 0.0023 | -- | -97.73 | -62.52 | -107.95 | -- | -40.26 | -- |
| CF PharmTech Inc | 686.31m | 31.54m | 15.42bn | 574.00 | 489.55 | 14.17 | 149.63 | 22.47 | 0.0766 | 0.0766 | 1.67 | 2.64 | -- | -- | -- | -- | -- | -- | -- | -- | 80.18 | -- | 4.60 | -- | 1.89 | -- | 0.076 | -- | 9.23 | -- | -33.53 | -- | -- | -- |
| Zai Lab Ltd | 3.60bn | -1.37bn | 15.44bn | 1.78k | -- | 2.71 | -- | 4.29 | -1.25 | -1.25 | 3.29 | 5.06 | 0.3903 | 3.12 | 4.81 | -- | -14.89 | -30.44 | -21.37 | -36.84 | 61.15 | 63.11 | -38.15 | -128.85 | 2.27 | -- | 0.2223 | -- | 15.33 | 56.54 | 31.73 | -- | 4.70 | -- |
| Vigonvita Life Sciences Co Ltd | -100.00bn | -100.00bn | 16.58bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -94.07 | -- | -1,848.73 | -- | -- | -- |
| HUTCHMED (China) Ltd | 4.71bn | 3.65bn | 18.48bn | 1.78k | 5.06 | 1.92 | 4.92 | 3.92 | 4.18 | 4.18 | 5.40 | 11.02 | 0.3966 | 7.09 | 3.86 | 2,600,620.00 | 30.79 | -9.55 | 40.72 | -13.77 | 44.15 | 39.84 | 77.64 | -20.32 | 4.51 | -- | 0.07 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Ab&B Bio Tech Co Ltd JS | 367.92m | -255.04m | 20.62bn | 583.00 | -- | 539.00 | -- | 56.03 | -0.6482 | -0.6482 | 0.9351 | 0.0972 | -- | -- | -- | -- | -- | -- | -- | -- | 67.29 | -- | -69.32 | -- | 0.3162 | -9.49 | 0.9646 | -- | 397.65 | -- | 39.09 | -- | -- | -- |
Data as of Mar 05 2026. Currency figures normalised to Ascletis Pharma Inc's reporting currency: Hong Kong Dollar HKD
10.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GIC Pte Ltd. (Investment Management)as of 03 Feb 2026 | 64.13m | 6.42% |
| Fullgoal Asset Management (HK) Ltd.as of 30 Jun 2025 | 15.27m | 1.53% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 14.45m | 1.45% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 2.58m | 0.26% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.09m | 0.21% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2025 | 1.73m | 0.17% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 1.68m | 0.17% |
| State Street Global Advisors Ltd.as of 05 Feb 2026 | 1.64m | 0.16% |
| Exchange Traded Concepts LLCas of 05 Feb 2026 | 1.32m | 0.13% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 750.00k | 0.08% |
More ▼
Data from 30 Jun 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
